Precision BioSciences, Inc.
DTIL
NASDAQ·Healthcare·Biotechnology·Mkt cap $95.8M
$7.47
▲ +1.36%
P/E
-2.15
Mkt Cap
$95.8M
52-Wk Range
$3.53–$9.62
52-Week Range
$3.53 - $9.62
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 50.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary ARCUS genome editing platform with in vivo gene editing capabilities
- Stealth cell technology minimizing chromosome abnormalities in CAR T development
- Strategic partnerships with Servier and other leading pharmaceutical companies
- Experienced clinical development team with advancing pipeline in high-need oncology indications
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Advancement of clinical trials for CD19 and BCMA-targeted CAR T therapies
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+10.3% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying DTIL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 2, 2026
AUG 6, 2026
Reported EPS of -$1.26 vs -$0.80 consensus (-56.7% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-56.7%
Revenue trend · last 8Q
—
—
-100%
-100%
-98%
+5261%
+37272%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$576.0K
$638.0K
$29.0K
$18.0K
$13.0K
$34.2M
$10.8M
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Oppenheimer · Jun 9, 2026
vs Industry
How DTIL stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related